英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字,中文词皆可:

behindhand    
a. 迟的,落后的
ad. 迟地,落后地

迟的,落後的迟地,落後地

behindhand
adv 1: in debt; "he fell behind with his mortgage payments"; "a
month behind in the rent"; "a company that has been run
behindhand for years"; "in arrears with their utility
bills" [synonym: {behind}, {behindhand}, {in arrears}]
adj 1: behind schedule; "was behindhand with the rent"

Behindhand \Be*hind"hand`\, adv. & a. [Behind hand.]
[1913 Webster]
1. In arrears financially; in a state where expenditures have
exceeded the receipt of funds.
[1913 Webster]

2. In a state of backwardness, in respect to what is
seasonable or appropriate, or as to what should have been
accomplished; not equally forward with some other person
or thing; dilatory; backward; late; tardy; as, behindhand
in studies or in work.
[1913 Webster]

In this also [dress] the country are very much
behindhand. --Addison.
[1913 Webster]


请选择你想看的字典辞典:
单词字典翻译
behindhand查看 behindhand 在百度字典中的解释百度英翻中〔查看〕
behindhand查看 behindhand 在Google字典中的解释Google英翻中〔查看〕
behindhand查看 behindhand 在Yahoo字典中的解释Yahoo英翻中〔查看〕





安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Adstiladrin: Uses, Dosage, Side Effects Warnings - Drugs. com
    Adstiladrin (nadofaragene firadenovec-vncg) is a gene therapy used to treat high-risk Bacillus CalmetteGuérin (BCG)-unresponsive non-muscle invasive bladder cancer Includes Adstiladrin side effects, interactions and indications
  • Bladder Cancer Treatment Options
    ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors
  • Package Insert - ADSTILADRIN
    ADSTILADRIN® is indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-Muscle Invasive Bladder Cancer (NMIBC) with carcinoma in situ (CIS
  • Nadofaragene Firadenovec-vncg - NCI - National Cancer Institute
    Nadofaragene firadenovec-vncg is approved to treat: Non-muscle–invasive bladder cancer with carcinoma in situ It is used in adults whose cancer does not respond to treatment with bacillus Calmette-Guérin (BCG) and has a high risk of coming back Nadofaragene firadenovec-vncg is also being studied in the treatment of other types of cancer
  • Treatment With ADSTILADRIN® (nadofaragene firadenovec-vncg)
    INDICATION ADSTILADRIN is a treatment for adults who have all the following: High-risk non–muscle-invasive bladder cancer (NMIBC) Cancer that is not responding to Bacillus Calmette-Guérin (BCG) therapy Carcinoma in situ (CIS) with or without other high-grade tumors IMPORTANT SAFETY INFORMATION Who should not receive ADSTILADRIN? Do not receive ADSTILADRIN if you have a sensitivity to
  • Dosing | ADSTILADRIN® (nadofaragene firadenovec-vncg)
    ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors
  • FDA Approves Label Update for Nadofaragene Firadenovec in . . .
    The FDA has approved a label update to nadofaragene firadenovec-vncg (Adstiladrin) that introduces an accelerated water bath thawing method completed in approximately 25 minutes, a change intended to streamline clinical preparation for health care teams managing patients with high risk non–muscle-invasive bladder cancer (NMIBC), according to a manufacturer news release 1 Nadofaragene
  • Nadofaragene firadenovec-vncg Intravesical - healthwise. net
    Nadofaragene firadenovec-vncg is used to treat a certain type of bladder cancer that was not effectively treated with another medication (Bacillus Calmette-Guerin; BCG therapy) Nadofaragene firadenovec-vncg is in a class of medications called gene
  • Nadofaragene Firadenovec: First Approval - PubMed
    Abstract Nadofaragene firadenovec (nadofaragene firadenovec-vncg; Adstiladrin ®) is a non-replicating adenoviral vector-based gene therapy developed by Ferring Pharmaceuticals for the treatment of high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) Nadofaragene firadenovec constitutes vector DNA that encodes for interferon (IFN)-α2b and is the
  • U. S. FDA Approves Label Update to Accelerate Thaw Time for . . .
    Adstiladrin ® (nadofaragene firadenovec-vncg) is the first and only FDA-approved intravesical non-replicating gene-therapy for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors (±Ta T1)





中文字典-英文字典  2005-2009